Biotech entity
Every one of those 2 sits in a single category, gene-therapy. Of the tracked stories, 2 of 2 also mention AMT-130, the most common co-covered peer. Each carries 2.5 original sources on average. We currently track 2 Biotech stories that mention HEMGENIX, all published on August 5, 2026.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, gene-therapy. Of the tracked stories, 2 of 2 also mention AMT-130, the most common co-covered peer. Each carries 2.5 original sources on average. We currently track 2 Biotech stories that mention HEMGENIX, all published on August 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HEMGENIX. Shared-story counts are live from our verified record — not editorial picks.
Four-Year Follow-Up Data from AMT-130 Pivotal Study
Durability of gene therapy effect expected to be reported, a key factor for regulatory decisions.
Regulatory Submissions for AMT-130 in Huntington's Disease (Planned)
uniQure aims to file for U.S. and U.K. approval in Q3 2026, targeting accelerated pathways.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
AMT-260 Preliminary Data and AMT-191 Further Analyses
Six-month follow-up from the Phase I/IIa AMT-260 trial in epilepsy and new Fabry data presented.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
Updated AMT-191 Phase I/II Data in Fabry Disease
Interim data demonstrate sustained enzyme activity and safety in Fabry disease patients.
Positive Topline Data for AMT-130 in Huntington's Disease
uniQure reports positive pivotal Phase I/II data, showing statistically significant improvements in disease markers.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
uniQure's AMT-130 for Huntington's disease is on track for U.S. and U.K. regulatory filings in Q3 2026, following positive pivotal data. Pipeline updates for AMT-191 and AMT-260 in Fabry disease and epilepsy show a broadening gene therapy platform.
Source: rttnews.com · finanzen.ch
HEMGENIX is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
